Are We Ready for Migrastatics?
Metastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/8/1845 |
| _version_ | 1797524355641507840 |
|---|---|
| author | Jonathan Solomon Magdalena Raškova Daniel Rösel Jan Brábek Hava Gil-Henn |
| author_facet | Jonathan Solomon Magdalena Raškova Daniel Rösel Jan Brábek Hava Gil-Henn |
| author_sort | Jonathan Solomon |
| collection | DOAJ |
| description | Metastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant cells. The concentration on invasion and metastasis can be one of the most meaningful advancements in cancer investigation. Importantly, metastasis-free survival (MFS) was recently approved by the Food and Drug Administration (FDA) as a novel primary endpoint in clinical trials and has been used to evaluate the prognosis of patients with nonmetastatic castration-resistant prostate cancer and soft tissue sarcoma. This new definition enables to shift the focus of research and development in cancer therapeutics toward metastasis and to change the emphasis from using tumor shrinkage as a benchmark for indicating the efficacy of treatment to using MFS as a more representative endpoint for antimetastatic drugs. This perspective outlines the possibility to use this novel endpoint in other solid cancers, and examples of large clinical trials are given in which MFS is defined as an endpoint and/or in which antimetastatic strategies are being examined. These advances now open the door for the rapid development of antimetastatic therapies, which could be used in combination with standard cytotoxic cancer therapies. With pioneer research on metastasis prevention on the rise and the underlying biomechanisms of tumor cell motility and invasion explored further than ever before, we believe an intensified focus on antimetastatic properties will shape this era of cancer translational research. |
| first_indexed | 2024-03-10T08:56:11Z |
| format | Article |
| id | doaj.art-1309c11952404ebba2922ada58c7519e |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T08:56:11Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-1309c11952404ebba2922ada58c7519e2023-11-22T07:08:10ZengMDPI AGCells2073-44092021-07-01108184510.3390/cells10081845Are We Ready for Migrastatics?Jonathan Solomon0Magdalena Raškova1Daniel Rösel2Jan Brábek3Hava Gil-Henn4Cell Migration and Invasion Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, IsraelLaboratory of Cancer Cell Invasion, Department of Cell Biology, Charles University, Viničná 7, 128 44 Prague, Czech RepublicLaboratory of Cancer Cell Invasion, Department of Cell Biology, Charles University, Viničná 7, 128 44 Prague, Czech RepublicLaboratory of Cancer Cell Invasion, Department of Cell Biology, Charles University, Viničná 7, 128 44 Prague, Czech RepublicCell Migration and Invasion Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, IsraelMetastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant cells. The concentration on invasion and metastasis can be one of the most meaningful advancements in cancer investigation. Importantly, metastasis-free survival (MFS) was recently approved by the Food and Drug Administration (FDA) as a novel primary endpoint in clinical trials and has been used to evaluate the prognosis of patients with nonmetastatic castration-resistant prostate cancer and soft tissue sarcoma. This new definition enables to shift the focus of research and development in cancer therapeutics toward metastasis and to change the emphasis from using tumor shrinkage as a benchmark for indicating the efficacy of treatment to using MFS as a more representative endpoint for antimetastatic drugs. This perspective outlines the possibility to use this novel endpoint in other solid cancers, and examples of large clinical trials are given in which MFS is defined as an endpoint and/or in which antimetastatic strategies are being examined. These advances now open the door for the rapid development of antimetastatic therapies, which could be used in combination with standard cytotoxic cancer therapies. With pioneer research on metastasis prevention on the rise and the underlying biomechanisms of tumor cell motility and invasion explored further than ever before, we believe an intensified focus on antimetastatic properties will shape this era of cancer translational research.https://www.mdpi.com/2073-4409/10/8/1845cancer metastasisclinical trialsmetastasis-free survivalmetastasis inhibitorresearch and development |
| spellingShingle | Jonathan Solomon Magdalena Raškova Daniel Rösel Jan Brábek Hava Gil-Henn Are We Ready for Migrastatics? Cells cancer metastasis clinical trials metastasis-free survival metastasis inhibitor research and development |
| title | Are We Ready for Migrastatics? |
| title_full | Are We Ready for Migrastatics? |
| title_fullStr | Are We Ready for Migrastatics? |
| title_full_unstemmed | Are We Ready for Migrastatics? |
| title_short | Are We Ready for Migrastatics? |
| title_sort | are we ready for migrastatics |
| topic | cancer metastasis clinical trials metastasis-free survival metastasis inhibitor research and development |
| url | https://www.mdpi.com/2073-4409/10/8/1845 |
| work_keys_str_mv | AT jonathansolomon arewereadyformigrastatics AT magdalenaraskova arewereadyformigrastatics AT danielrosel arewereadyformigrastatics AT janbrabek arewereadyformigrastatics AT havagilhenn arewereadyformigrastatics |